Replimune Group, Inc. (REPL)
Nasdaq · Healthcare · Biotechnology
$13.15+0.61%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $1.2B
- 52-week range
- $1.50 – $16.33
- 52-week change
- +179.27%
- EPS (trailing)
- −$3.15
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Mar 2026
- Net income
- −$314M
- Diluted EPS
- −$3.38
- Free cash flow
- −$285M
From the company’s annual report on SEC EDGAR.
About Replimune Group, Inc.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Headquarters: Woburn, United States · 465 employees · replimune.com